SEE Reports Q1 2023 Results

Silgan Holdings Inc. announced that, as part of the continuation of its long-term succession planning, its Board of Directors has appointed Adam J. Greenlee as Chief Executive Officer of the Company, effective September 1, 2021. Mr. Greenlee will also continue as President of the Company. Mr. Greenlee joined Silgan in 2005 and ran its North American Closures operations prior to being appointed Executive Vice President of the Company in October 2007. Mr. Greenlee was named Chief Operating Officer of the Company in 2009 and was appointed President of the Company in April 2019. Tony Allott has served as Chief Executive Officer of the Company since March 2006, only its second CEO since its founding in 1987. Mr. Allott will continue to serve as Executive Chairman of the Company. “Adam and I have worked closely together on every major activity of Silgan for the past decade and he has been responsible for the oversight of each of our operating businesses in recent years. Just as importantly, Adam understands and personifies the unique culture of our Company and has consistently shown his ability to deliver results as Silgan has continued on its path of growth and success. While I am sure his leadership will explore new ideas and opportunities, I am equally confident it will be founded on the ideals and principles that have served us so well in the past,” said Tony Allott, Chairman and CEO.

Highcon announced a $8M investment by Sealed Air Corporation in the context of a strategic collaboration between the two companies. The scope of the strategic collaboration includes the following components: *Developing new product offerings, expansion into new segments and enabling manufacturing efficiencies by leveraging Highcon technology *$8M investment in the form of convertible debt and 15% warrants to be converted by the 5th anniversary of the Effective Date at a price of 3.1 NIS per share. *Additional warrants to be granted against possible future purchases up to $20 million of Highcon's products and services over a period of 3 years.

Sonoco ThermoSafe is building PharmaPortal™, a vendor-neutral blockchain platform for use by pharmaceutical manufacturers and carriers. Built on IBM Blockchain Transparent Supply, PharmaPortal intends to address the industry’s needs to trace assets across many different supply chain participants, record a single version of the truth on all events generated on a package’s journey, integrate this data with that of other businesses across an industry-scale network, and provide access controls to help ensure each data owner maintains control over who can access it on the network. The openly governed blockchain network built on open source technology will initially focus on end-to-end traceability of temperature-controlled drugs, such as vaccines, and provide an audit trail of environmental condition monitoring to help protect the efficacy of these lifesaving, life-extending and life-enhancing medicines. To help drive its development, Sonoco will invite industry leaders to collaborate on the initiative to optimize the safety and efficiency of global temperature controlled pharmaceutical distribution.